Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 6/20 | 0.57 |
| ▸ | KIT | P10721 | 5/20 | 0.57 |
| ▸ | CSF1R | P07333 | 4/20 | 0.57 |
| ▸ | FLT1 | P17948 | 4/20 | 0.57 |
| ▸ | ABL1 | P00519 | 3/20 | 0.57 |
| ▸ | LCK | P06239 | 3/20 | 0.57 |
| ▸ | FYN | P06241 | 3/20 | 0.57 |
| ▸ | LYN | P07948 | 3/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.57 |
| ▸ | FLT4 | P35916 | 3/20 | 0.57 |
| ▸ | BLK | P51451 | 3/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.56 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28078227 | 0.84 | CA12 (0.60) | KDRCA12CA1CA2CA9 | |
| SCHEMBL1923952 | 0.84 | KDR (0.58) | KDRCA12CA1CA2CA9 | |
| SCHEMBL1923687 | 0.83 | CA12 (0.57) | KDRCA12CA1CA2CA9 | |
| SCHEMBL4477408 | 0.82 | KDR (0.61) | KDRCA12CA1CA2CA9 | |
| SCHEMBL1923690 | 0.82 | CA12 (0.55) | KDRCA12CA1CA2CA9 | |
| SCHEMBL1924032 | 0.82 | FLT3 (0.59) | KDRCA12CA1CA2CA9 | |
| SCHEMBL1924576 | 0.82 | CA12 (0.55) | KDRCA12CA1CA2CA9 | |
| SCHEMBL4662498 | 0.82 | KDR (0.60) | KDRCA12CA1CA2CA9 | |
| SCHEMBL1923906 | 0.81 | CA12 (0.54) | KDRCA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL1924264 | 0.81 | CA12 (0.54) | KDRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856043-B1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2011-06-08 | — | — | EP | claimed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | claimed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | claimed |
| EP-1856043-A1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2007-11-21 | — | — | EP | claimed |
| WO-2006082309-A1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2006-08-10 | — | — | WO | claimed |
| EP-1856043-B1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2011-06-08 | — | — | EP | disclosed |
| EP-1856043-B1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2011-06-08 | — | — | EP | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-7560571-B2 | Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-07-14 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| EP-1856043-A1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | Aventis Pharma S.A. (FR) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006082309-A1 | 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045542-A1 | Substituted Pyrroles and Imidazoles, Compositions Containing Same, Manufacturing Process Therefor and Use Thereof | WEE1, WEE2, FARS2 | KDR 1126/4885CA12 3831/4885CA1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.